A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Sponsor
Hoffmann-La Roche
Study ID
NCT01153971
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will evaluate the efficacy and safety of MabThera in combination chemotherapy, followed by maintenance treatment with MabThera. The anticipated time on study treatment is 1-2 years, and the target sample size is \<100 individuals.

Key Dates

Start date
Jul 20, 2005
Status verified
Jun 2017
Primary completion
Sep 24, 2010
Completion
Sep 24, 2010

Study Design

Enrollment
47 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1

Primary Outcome Measure

Percentage of Participants Remaining Failure-Free After 2 Years From Treatment Start Date [ Time Frame: Month 28 ]

Related Studies